Active Clinical Trials

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

By April 24, 2017 No Comments

Condition

Malignant Pleural Mesothelioma

Estimated Enrollment: 12

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 1716-12

Study First Received: October 22, 2012

Last Updated: September 8, 2016

Estimated Primary Completion Date: March 2017

 

Primary Outcome Measures:

Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.|Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.

Sponsors and Collaborators:

Virttu Biologics Limited

Website Link: https://ClinicalTrials.gov/show/NCT01721018

Leave a Reply

Call Now ButtonCall Now